View in EDS HTML Full Text PDF Full Text

Cost-effectiveness analysis of ribociclib versus abemaciclib as first-line treatments for postmenopausal women with HR+/HER2- advanced breast cancer: a Medicare perspective.

Saved in:
Bibliographic Details
Title: Cost-effectiveness analysis of ribociclib versus abemaciclib as first-line treatments for postmenopausal women with HR+/HER2- advanced breast cancer: a Medicare perspective.
Authors: Tarantino P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Sammons S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Gadi VK; Translational Oncology Program, University of Illinois Cancer Center, Chicago, IL, USA., Pathak P; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Sopher G; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Delea T; Avalere Health, Boston, MA, USA., Stellato D; Avalere Health, Boston, MA, USA.
Source: Journal of medical economics [J Med Econ] 2025 Dec; Vol. 28 (1), pp. 2125-2134. Date of Electronic Publication: 2025 Dec 05.
Publication Type: Journal Article
Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 9892255 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1941-837X (Electronic) Linking ISSN: 13696998 NLM ISO Abbreviation: J Med Econ Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41347936
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Cost-effectiveness analysis of ribociclib versus abemaciclib as first-line treatments for postmenopausal women with HR+/HER2- advanced breast cancer: a Medicare perspective.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Tarantino+P%22">Tarantino P</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Sammons+S%22">Sammons S</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Gadi+VK%22">Gadi VK</searchLink>; Translational Oncology Program, University of Illinois Cancer Center, Chicago, IL, USA.<br /><searchLink fieldCode="AU" term="%22Pathak+P%22">Pathak P</searchLink>; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Sopher+G%22">Sopher G</searchLink>; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Delea+T%22">Delea T</searchLink>; Avalere Health, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Stellato+D%22">Stellato D</searchLink>; Avalere Health, Boston, MA, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229892255%22">Journal of medical economics</searchLink> [J Med Econ] 2025 Dec; Vol. 28 (1), pp. 2125-2134. <i>Date of Electronic Publication: </i>2025 Dec 05.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9892255 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1941-837X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2213696998%22">13696998 </searchLink><i>NLM ISO Abbreviation: </i>J Med Econ <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41347936
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1080/13696998.2025.2594951
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2125
    Titles:
      – TitleFull: Cost-effectiveness analysis of ribociclib versus abemaciclib as first-line treatments for postmenopausal women with HR+/HER2- advanced breast cancer: a Medicare perspective.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Tarantino P
      – PersonEntity:
          Name:
            NameFull: Sammons S
      – PersonEntity:
          Name:
            NameFull: Gadi VK
      – PersonEntity:
          Name:
            NameFull: Pathak P
      – PersonEntity:
          Name:
            NameFull: Sopher G
      – PersonEntity:
          Name:
            NameFull: Delea T
      – PersonEntity:
          Name:
            NameFull: Stellato D
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: 2025 Dec
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1941-837X
          Numbering:
            – Type: volume
              Value: 28
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Journal of medical economics
              Type: main
ResultId 1